The best deals are not always the quickest to close, as Teva Pharmaceuticals learned in 2016 after its much-lauded acquisition of Allergan’s generic business, Actavis Generics. In its acquisition of ...

The complaint alleges nearly two dozen pharmaceutical companies colluded to limit competition, causing costs for certain ...

Teva has agreed to pay a whopping $1.2 billion ... Other cases in the US include the FTC's pursuit of AbbVie subsidiary Solvay and Actavis unit Watson on testosterone replacement therapy product ...

The management of Israeli pharma group Teva has laid out its strategy for ... accompanied its takeover in 2017 of generic drugmaker Actavis, albeit reduced from a high of $34 billion to a current ...

and the company has reduced its net debt from north of $35 billion following the Actavis buyout in 2016 to roughly $15.7 billion, as of the end of September. With Teva growing, once more ...